Enhanced Investments - Financial Portal

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

Published: 2023-08-14 12:05:00 ET

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that multiple abstracts highlighting FYCOMPA® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023 in Dublin, Ireland. These are presentations by Eisai Co., Ltd. ("Eisai"), which holds the rights to FYCOMPA in countries and regions outside the U.S. Some abstracts will also be considered for publication in Epilepsia following the IEC.

The accepted abstracts and presentations detail the results from clinical and real-world studies, further documenting the uses of perampanel in both focal and generalized epilepsy across a diverse range of patients.

“These findings, which are being presented at IEC, further validate and add to the growing body of evidence supporting the benefits of perampanel in the treatment of seizure disorders,” said Gary Ingenito, MD, PhD, Chief Medical and Regulatory Officer of Catalyst. “We are pleased this investigative work will be presented at such a prestigious forum.”

Details of the Accepted Abstracts are as follows:

Title: Perampanel for Treatment of Focal and Generalised Epilepsy in Everyday Clinical Practice: Evidence from PERMIT 2Authors:Eugen Trinka, Robert Wechsler, Wendyl D’Souza, Tony Wu, Imad Najm, Leock Ngo, Rob McMurray, Vicente VillanuevaOral Presentation number: 370Oral Presentation Session Name: Drug Therapy 1Session:Sunday, September 3, 2023, at 3:30 PM-4:30 PM BST(Eugen Trinka will present for 10 minutes: 3:35 PM-3:45 PM)Presenter:Eugen TrinkaLocation: Room Liffey B

Title: Study 603: Analysis of Effectiveness and Safety of Perampanel in a Multicentre, Retrospective Study in Patients from Korea with Focal-Onset Seizures who Converted to MonotherapyAuthors:Sung Chul Lim, Won Gu Lee, Dong Wook Kim, Kwang Ki Kim, Young-Min Shon, Jihyun Park, Yoona Lee, Dae-Won SeoPoster number: P048Digital Poster* Session and Rapid-Fire Presentation Name: Drug Therapy 2Rapid Fire Presentation (2-minute session):Time and Date:Sunday, September 3, 2023, at 2:00 PM-2:30 PM BSTPresenter:Sung Chul LimLocation:Digital Poster Station: Level 3 Foyer - Station C

Title: ELEVATE Study 410: Assessment of Cognition (EpiTrack®) Following Perampanel (Monotherapy/First Adjunctive) in Patients with Epilepsy and a History of Psychiatric/Behavioral EventsAuthors: Vineet Punia, Omar Samad, Stella Ngo, Dinesh Kumar, Manoj Malhotra Poster number: P149In-person & Digital Poster Session Name: Drug TherapyPresentation:Monday, September 4, 2023, at 1:30 PM-3:00 PM BSTPresenter:Vineet PuniaLocation: Poster Hall

Title: A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents (AMPA): Assessment of Impact of Perampanel on Seizure Control, Sleep and Quality of LifeAuthors:Giovanni Assenza, Martina Chiacchiaretta, Anna Patten, Ricardo Sáinz-Fuertes, Anna GentilePoster number: P240Digital Poster* (Available on the Congress app, online platform, and digital poster terminals at the congress venue; Q&A chat box function also available)

Title: Perampanel for Treatment of Adolescent Patients (Aged ≥12 to

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.